Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
Protocol ID
Firefly-2
Disease (Sub Disease)
Low-Grade Glioma
Diagnosis Stage
Newly diagnosed
Sponsor
Day One Biopharmaceuticals, Inc.
Collaborators
SIOPe Brain Tumor Group LOGGIC Consortium
Trial Status
Preparing to Open
Study Type
Treatment
Phase
Phase 3
Age Eligibility
up to 25 Years
International registry ID's
NCT05566795
Back to Registry
Study Title A Phase 3 Randomized International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
Protocol ID Firefly-2
Disease (Sub Disease) Low-Grade Glioma
Diagnosis Stage Newly diagnosed
Sponsor Day One Biopharmaceuticals, Inc.
Collaborators SIOPe Brain Tumor Group LOGGIC Consortium
Links https://clinicaltrials.gov/ct2/show/NCT05566795
Trial Status Preparing to Open
Study Type Treatment
Phase Phase 3
Age Eligibility up to 25 Years
International registry ID's NCT05566795